• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奎奴普丁/达福普汀与RPR 106972的比较活性及培养基对体外试验结果的影响。

Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results.

作者信息

King A, May J, Phillips I

机构信息

Microbiology Department, UMDS, London, UK.

出版信息

J Antimicrob Chemother. 1998 Dec;42(6):711-9. doi: 10.1093/jac/42.6.711.

DOI:10.1093/jac/42.6.711
PMID:10052893
Abstract

Quinupristin/dalfopristin and RPR 106972 were active in vitro against a wide range of aerobic Gram-positive organisms including Enterococcus faecium. However, most isolates of Enterococcus faecalis were resistant or of intermediate sensitivity. Against Staphylococcus aureus quinupristin/dalfopristin was more active but for all other species the range of activity of the two drugs was the same or RPR 106972 was more active. RPR 106972 was also more active against the respiratory pathogens Haemophilus influenzae and Moraxella catarrhalis. Quinupristin/dalfopristin MICs for isolates of H. influenzae (1-8 mg/L) clustered around the breakpoint. There were differences in the quality of growth, but little difference in MICs or zone diameters was obtained on three different media: Mueller-Hinton (MHA), Iso-Sensitest (ISA), and Diagnostic Sensitivity Test (DST) agars. The addition of blood to the medium increased MICs 2- to 4-fold, with MHA showing the greatest increase, and reduced zone diameters around quinupristin/dalfopristin discs by 3-4 mm, with the greatest effect on ISA.

摘要

奎奴普丁/达福普汀和RPR 106972在体外对包括粪肠球菌在内的多种需氧革兰氏阳性菌具有活性。然而,大多数粪肠球菌分离株具有抗性或中度敏感。对于金黄色葡萄球菌,奎奴普丁/达福普汀活性更强,但对于所有其他菌种,两种药物的活性范围相同或RPR 106972活性更强。RPR 106972对呼吸道病原体流感嗜血杆菌和卡他莫拉菌也更具活性。流感嗜血杆菌分离株的奎奴普丁/达福普汀MIC值(1 - 8mg/L)集中在折点附近。生长质量存在差异,但在三种不同培养基(穆勒-欣顿琼脂(MHA)、异感测试琼脂(ISA)和诊断敏感性测试琼脂(DST))上,MIC值或抑菌圈直径差异不大。向培养基中添加血液会使MIC值增加2至4倍,其中MHA增加幅度最大,并且会使奎奴普丁/达福普汀纸片周围的抑菌圈直径减小3至4mm,对ISA的影响最大。

相似文献

1
Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results.奎奴普丁/达福普汀与RPR 106972的比较活性及培养基对体外试验结果的影响。
J Antimicrob Chemother. 1998 Dec;42(6):711-9. doi: 10.1093/jac/42.6.711.
2
In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.奎奴普丁/达福普汀在台湾对革兰氏阳性菌流感嗜血杆菌和卡他莫拉菌的体外活性
Zhonghua Yi Xue Za Zhi (Taipei). 2000 Jun;63(6):433-9.
3
Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
J Antimicrob Chemother. 1997 May;39 Suppl A:81-5. doi: 10.1093/jac/39.suppl_1.81.
4
In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.奎奴普丁/达福普汀的体外和体内抗菌活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:15-21. doi: 10.1093/jac/39.suppl_1.15.
5
Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae.奎奴普丁/达福普汀及其成分对流感嗜血杆菌的活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:69-73. doi: 10.1093/jac/39.suppl_1.69.
6
In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Diagn Microbiol Infect Dis. 1997 Jul;28(3):139-47. doi: 10.1016/s0732-8893(97)00023-0.
7
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀:用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
8
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.达托霉素、利奈唑胺和奎奴普丁/达福普汀对某大型癌症中心革兰氏阳性菌分离株的体外活性比较
Diagn Microbiol Infect Dis. 2005 Jul;52(3):255-9. doi: 10.1016/j.diagmicrobio.2005.02.015.
9
Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media.在药敏试验培养基中对奎奴普丁/达福普汀(Synercid)和RPR 106972稳定性的评估。
Int J Antimicrob Agents. 2000 Aug;15(4):291-7. doi: 10.1016/s0924-8579(00)00180-1.
10
In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).奎奴普丁/达福普汀(Synercid)的体外活性及抗生素后效应
Chemotherapy. 2001 Jul-Aug;47(4):243-9. doi: 10.1159/000048530.

引用本文的文献

1
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.新型口服链阳菌素XRP 2868与其他药物相比,对肺炎链球菌和嗜血杆菌属的活性。
Antimicrob Agents Chemother. 2003 Oct;47(10):3270-4. doi: 10.1128/AAC.47.10.3270-3274.2003.
2
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀:用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
3
Antibiotic resistance: a current perspective.
抗生素耐药性:当前视角
Br J Clin Pharmacol. 1999 Aug;48(2):109-24. doi: 10.1046/j.1365-2125.1999.00997.x.